Proficio Capital Partners LLC grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 4,418.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 147,360 shares of the company's stock after acquiring an additional 144,099 shares during the period. Proficio Capital Partners LLC's holdings in Moderna were worth $6,127,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the last quarter. Compass Planning Associates Inc purchased a new stake in shares of Moderna during the 4th quarter valued at $37,000. Venturi Wealth Management LLC raised its position in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB grew its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares during the period. Finally, Blue Trust Inc. increased its stake in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after acquiring an additional 388 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts have recently issued reports on MRNA shares. Hsbc Global Res upgraded Moderna from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. Barclays lowered shares of Moderna from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Piper Sandler reaffirmed an "overweight" rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. Finally, Evercore ISI set a $50.00 price objective on Moderna in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $60.63.
Get Our Latest Research Report on MRNA
Moderna Stock Performance
Shares of NASDAQ MRNA traded up $1.31 during midday trading on Friday, hitting $35.61. The company's stock had a trading volume of 17,268,156 shares, compared to its average volume of 12,692,892. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The firm's fifty day moving average price is $36.69 and its 200-day moving average price is $49.67. The firm has a market cap of $13.74 billion, a P/E ratio of -3.84 and a beta of 1.86.
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Recommended Stories
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
